Analysts Are Truly Divided on Chemours after Its 3Q16 Earnings
Among the analysts covering Chemours’ stock, 33.33% analysts recommended a “buy,” while 33.33% issued a “hold,” and the remaining 33.33% issued a “sell.”
Nov. 10 2016, Updated 11:04 a.m. ET
![uploads///Part Q Earnings CC](https://media.marketanalyst.us/brand-img/Fwu8_FLZo/480x251/uploads/2016/11/Part-6-3Q16-Earnings-CC-1.png 480w, https://media.marketanalyst.us/brand-img/Fwu8_FLZo/640x335/uploads/2016/11/Part-6-3Q16-Earnings-CC-1.png 640w, https://media.marketanalyst.us/brand-img/Fwu8_FLZo/768x402/uploads/2016/11/Part-6-3Q16-Earnings-CC-1.png 768w, https://media.marketanalyst.us/brand-img/Fwu8_FLZo/1024x536/uploads/2016/11/Part-6-3Q16-Earnings-CC-1.png 1024w, https://media.marketanalyst.us/brand-img/Fwu8_FLZo/1280x670/uploads/2016/11/Part-6-3Q16-Earnings-CC-1.png 1280w, https://media.marketanalyst.us/brand-img/Fwu8_FLZo/1440x753/uploads/2016/11/Part-6-3Q16-Earnings-CC-1.png 1440w, https://media.marketanalyst.us/brand-img/Fwu8_FLZo/1600x837/uploads/2016/11/Part-6-3Q16-Earnings-CC-1.png 1600w, https://media.marketanalyst.us/brand-img/Fwu8_FLZo/2160x1130/uploads/2016/11/Part-6-3Q16-Earnings-CC-1.png 2160w)
Analyst consensus
Analysts are truly divided on Chemours following the company’s 3Q16 earnings. Only a few analysts have changed their recommendations after the earnings release. Among the analysts covering the stock, 33.33% analysts have recommended a “buy,” while 33.33% have recommended a “hold,” and the remaining 33.33% have recommended a “sell.”
The consensus indicates a 12-month target price for of $15.25, which implies a potential one-year return of -20.9% based on the stock’s closing price of $19.28 on November 7, 2016.
Individual brokerage firms
Individual recommendations from brokerage firms include the following:
- On November 8, Goldman Sachs (GS) rated Chemours as “buy/attractive,” with a 12-month target price of $23.00, which implies a potential one-year return of 19.30%, as compared to $19.28 on November 7.
- On November 8, J.P. Morgan (JPM) rated Chemours as “neutral,” with a price target of $20.00, which implies a 12-month potential return of 3.7%, based on the closing price of $19.28 on November 7.
- On November 7, Barclays (BCS) gave an “overweight” rating to Chemours, with a price target of $17.00, which implies a 12-month potential return of -11.8% over the November 7 closing price of $19.28
Notably, investors can indirectly hold Chemours by investing in the PowerShares DWA Basic Materials Momentum Portfolio (PYZ), which had 6.0% of its holdings in Chemours on November 7, 2016.